Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
Our study demonstrates that the combination of AGIs and ICIs significantly raises the risk of hemorrhage, underscoring the urgent need for enhanced monitoring protocols in clinical practice to improve treatment efficacy and safety.
Authors
- Pingping Long
- Ying Tuo
- Yuhui Yang (ORCID: https://orcid.org/0000-0002-4949-3745)
- Xiaoxiao Wang (ORCID: https://orcid.org/0000-0002-3996-7900)
Institutions
- Chongqing University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Chongqing Cancer Hospital (CN)
- Chongqing University of Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1527570
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52